Serán BioScience announced that it had completed an expansion to add eight state-of-the art process manufacturing suites at its facility in Bend, Oregon, adding around 130% more CGMP clinical manufacturing capacity. The suites will provide increased flexible capacity for late-stage clinical trial supply for small-molecule drugs.

The additional 8 state-of-the-art suites will provide increased flexible capacity for late-stage clinical trial supply for small-molecule medicines. Serán’s ‘Right-From-the-Start’ approach to commercially relevant drug product solutions includes bioavailability enhancement by improving both permeability and solubility, matrix tablet- and multiparticulate-based modified release, extensive capsule and immediate release/modified release tablet capabilities, and engineered particles for inhalation.

“Serán continues to see high demand for science-based drug product services,” commented Dan Smithey, Ph.D., President, CEO and Co-founder of Serán BioScience. “We are excited to announce the expansion at the site, where we can now provide mid- and large-scale manufacturing unit operations to support our clients’ journey from first-in-human studies through to pivotal trials and registration.”

The new suites are housed within the existing footprint of Serán’s campus in Bend, which includes 10 buildings and a combined 90,000 square-feet of space. The state-of-the-art facilities are equipped with the latest technologies that empower transformative pharmaceutical dosage-form solutions. The company offers clinical manufacturing capabilities at the site for a broad range of oral solid and inhaled dosage forms including unit operations in nano milling and micronization, particle engineering including dry and wet granulation, spray-dried dispersions, twin-screw melt extrusion, tablet compression, tablet coating, encapsulation, and clinical packaging and labeling. Its workforce at the site exceeds 190.

For more, please find the original story source here.